#ASN25: Eledon plots path forward for kidney transplant drug despite Phase 2 missnews2025-11-06T23:30:09+00:00November 6th, 2025|Endpoints News|
Eisai plots label expansion for subcutaneous Leqembi, details early launch progressnews2025-11-06T20:26:42+00:00November 6th, 2025|Endpoints News|
FDA approves J&J’s Darzalex for smoldering multiple myelomanews2025-11-06T20:20:50+00:00November 6th, 2025|Endpoints News|
Makary pushes bounds of FDA commissioner role on prices, drug reviews and personnelnews2025-11-06T20:08:18+00:00November 6th, 2025|Endpoints News|
FDA unveils second batch of commissioner voucher winnersnews2025-11-06T20:07:01+00:00November 6th, 2025|Endpoints News|
Updated: Trump lands sweeping cost cuts on Lilly, Novo weight loss drugsnews2025-11-06T17:04:00+00:00November 6th, 2025|Endpoints News|
Novo Nordisk raises Metsera bid again, hoping to top Pfizer’s latest offernews2025-11-06T15:56:47+00:00November 6th, 2025|Endpoints News|
Dyne changes plans for DM1 drug again; Dynavax licenses Vaxart’s Covid vaccinenews2025-11-06T15:43:37+00:00November 6th, 2025|Endpoints News|
#ASN25: Vera outlines full Phase 3 win for kidney drug, preps for FDA filing by year’s endnews2025-11-06T15:11:58+00:00November 6th, 2025|Endpoints News|
UPS, Cencora to expand their US operations; Evotec divests biosimilar business to Sandoznews2025-11-06T14:36:04+00:00November 6th, 2025|Endpoints News|
